Join
Live feed
·
PRReleasevia Quantisnow
Teva Pharmaceutical Industries Limited logo

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

ByQuantisnow·Wall Street's wire, on your screen.
TEVA· Teva Pharmaceutical Industries Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TEVA (Teva Pharmaceutical Industries Limited) and more on Quantisnow.